title: Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer.
abstract: We previously reported that indoleamine-2,3-dioxygenase (IDO) is associated with paclitaxel resistance and that IDO serves as a marker of poor prognosis in ovarian serous adenocarcinomas (SA). In this study, to explore the role of IDO in the development of various histological types of ovarian cancer, we further examined IDO expression not only in SA but also in other types of ovarian cancers. Expression of IDO protein was analyzed by immunohistochemistry for a total of 122 ovarian cancers including 40 SA, 67 clear cell adenocarcinomas (CCA), and 15 endometrioid adenocarcinomas (EA) with informed consent. Among these cases, there were 11 CCA accompanied with endometriosis and 60 cases with lymph node metastasis. We classified the samples into four categories by IDO staining pattern. IDO staining was positive in 57.5% of SA, 49.2% of CCA, and 73.3% of EA, respectively. The Kaplan-Meier survival curve showed a clear relationship between staining score and overall survival for patients with advanced (stages III and IV) SA (n=33) who underwent optimal surgery and paclitaxel-carboplatin (TC) chemotherapy as a first-line regimen. There was no association between IDO staining score and overall survival in the CCA cases. Eight of 11 cases (72.7%) of CCA accompanied by endometriosis presented identical staining patterns of IDO between CCA and endometriosis. In 43 of 60 cases (71.6%) with lymph node metastasis, the staining patterns of IDO showed a correspondence between the primary lesion and metastatic site. These results suggested that the increased synthesis of IDO protein was positively associated with impaired survival only in the serous type of ovarian cancer.
authors.affiliation: Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo 105-8461, Japan.
authors.forename: Miho
authors.initials: M
authors.lastname: Takao
authors.forename: Aikou
authors.initials: A
authors.lastname: Okamoto
authors.forename: Takashi
authors.initials: T
authors.lastname: Nikaido
authors.forename: Mitsuyoshi
authors.initials: M
authors.lastname: Urashima
authors.forename: Satoshi
authors.initials: S
authors.lastname: Takakura
authors.forename: Misato
authors.initials: M
authors.lastname: Saito
authors.forename: Motoaki
authors.initials: M
authors.lastname: Saito
authors.forename: Sanshiro
authors.initials: S
authors.lastname: Okamoto
authors.forename: Osamu
authors.initials: O
authors.lastname: Takikawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sasaki
authors.forename: Makoto
authors.initials: M
authors.lastname: Yasuda
authors.forename: Kazunori
authors.initials: K
authors.lastname: Ochiai
authors.forename: Tadao
authors.initials: T
authors.lastname: Tanaka
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis* / Q000378:metabolism; D018284:Cystadenocarcinoma, Serous / Q000201:enzymology / Q000401:mortality* / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000032:analysis* / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000201:enzymology / Q000401:mortality* / Q000473:pathology; D011379:Prognosis; D015996:Survival Rate; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase